3-cyclobutyl-1-(2-phenyl-quinolin-7-yl)-imidazol[1,5-a]pyrazin-8-ol | 1018838-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-cyclobutyl-1-(2-phenyl-quinolin-7-yl)-imidazol[1,5-a]pyrazin-8-ol
• 英文别名: 3-cyclobutyl-1-(2-phenylquinolin-7-yl)-7H-imidazo[1,5-a]pyrazin-8-one
• CAS: 1018838-78-2
• 化学式: C₂₅H₂₀N₄O
• 分子量: 392.46
• InChiKey: KMBNBWQPFLAEHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  7-(8-chloro-3-cyclobutylimidazo[1,5-a]pyrazin-1-yl)-2-phenylquinoline 在 盐酸 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 3-cyclobutyl-1-(2-phenyl-quinolin-7-yl)-imidazol[1,5-a]pyrazin-8-ol
  参考文献：
  名称：

  [EN] IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS
  [FR] DÉRIVÉS D'IMIDAZOPYRAZINOL POUR LE TRAITEMENT DES CANCERS

  摘要：

  化合物的结构式（I）及其药用盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1在此处定义，抑制IGF-IR酶，可用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和病况。

  公开号：

  WO2009091939A1

文献信息

• [EN] IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRAZINOL POUR LE TRAITEMENT DES CANCERS
  申请人：OSI PHARM INC

  公开号：WO2009091939A1

  公开（公告）日：2009-07-23

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-IR enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  化合物的结构式（I）及其药用盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1在此处定义，抑制IGF-IR酶，可用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和病况。
• IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS
  申请人：Mulvihill Mark J.

  公开号：US20110046144A1

  公开（公告）日：2011-02-24

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-IR enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  化合物公式(I)及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，能够抑制IGF-IR酶并用于治疗和/或预防过度增殖性疾病，如癌症、炎症、银屑病、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和疾病状态。
• Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors
  作者：Mark J. Mulvihill、Qun-Sheng Ji、Heather R. Coate、Andrew Cooke、Hanqing Dong、Lixin Feng、Kenneth Foreman、Maryland Rosenfeld-Franklin、Ayako Honda、Gilda Mak

  DOI：10.1016/j.bmc.2007.10.061

  日期：2008.2.1

  A series of novel, potent quinolinyl-derived imidazo[1,5-a]pyrazine IGF-IR (IGF-1R) inhibitors most notably, cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-plienylquinotin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine (AQIP)-is described. Synthetic details, structure-activity relationships, and in vitro biological activity are reported for the series. Key in vitro and in vivo biological results for AQIP are reported, including: inhibition of ligand-stimulated autophosphorylation of IGF-IR and downstream pathways in 3T3/huIGFIR cells; inhibition of proliferation and induction of DNA fragmentation in human tumor cell lines; a pharmacokinetic profile suitable for once-per-day oral dosing; antitumor activity in a 3T3/huIGFIR xenograft model; and effects on insulin and glucose levels. (C) 2007 Elsevier Ltd. All rights reserved.